🇺🇸 FDA

Intelligence · Patent portfolio

Regeneron UK Patents

Full USPTO pharma patent portfolio for Regeneron UK — grant dates, expiration, and drug cross-links.

Patents
837
Expiring ≤24m
26

Quick answer

Regeneron UK has 837 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 26 expire within 24 months — use filters for patent-cliff planning.

Page 7 of 18

  1. US 11504390

    Treatment of increased lipid levels with sterol regulatory element binding transcription factor 1 (SREBF1) inhibitors

    Expires Mon Nov 17 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 11498969

    Compositions and methods for treating juvenile idiopathic arthritis

    Expires Mon Nov 10 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 11498970

    Human antibodies to the human glucagon receptor and methods of use thereof to lower blood glucose or ketone levels

    Expires Mon Nov 10 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 11491237

    Cyclodextrin protein drug conjugates

    Expires Mon Nov 03 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 11492392

    Polynucleotides encoding anti-C5 antibodies

    Expires Mon Nov 03 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 11491222

    Method of treating lower back pain

    Expires Mon Nov 03 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 11485770

    Anti-VEGF protein compositions and methods for producing the same

    Expires Mon Oct 27 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 11485788

    Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an IL-4R inhibitor

    Expires Mon Oct 27 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 11485958

    HSD17B13 variants and uses thereof

    Expires Mon Oct 27 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 11485793

    Anti-MUC16 antibodies, antibody-drug conjugates, and bispecific antigen-binding molecules that bind MUC16 and CD3, and uses thereof

    Expires Mon Oct 27 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 11479602

    Methods of treating C5-associated diseases comprising administering anti-C5 antibodies

    Expires Mon Oct 20 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 11472870

    Pharmaceutical composition for safe and effective treatment of knee and/or hip pain

    Expires Mon Oct 13 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 11472861

    Methods for producing aflibercept in chemically defined media having reduced aflibercept variants

    Expires Mon Oct 13 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 11464830

    Treatment of inflammatory conditions by delivery of interleukin-1 receptor antagonist fusion protein

    Expires Mon Oct 06 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 11459374

    Anti-VEGF protein compositions and methods for producing the same

    Expires Mon Sep 29 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 11459373

    Anti-VEGF protein compositions and methods for producing the same

    Expires Mon Sep 29 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 11453721

    Bispecific anti-MUC16 x anti-CD28 antibodies and uses thereof

    Expires Mon Sep 22 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 11453714

    Human antibodies to influenza hemagglutinin

    Expires Mon Sep 22 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 11446389

    Maytansinoid derivatives, conjugates thereof, and methods of use

    Expires Mon Sep 15 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 11440950

    Anti-VEGF protein compositions and methods for producing the same

    Expires Mon Sep 08 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 11439683

    Anti-angiogenic therapy of metastatic colorectal cancer

    Expires Mon Sep 08 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 11434300

    Methods and antibody compositions for tumor treatment

    Expires Mon Sep 01 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 11421036

    Methods of treating eosinophilic esophagitis by administering an antibody which inhibits interleukin-4 receptor (IL-4R)

    Expires Mon Aug 18 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 11419318

    Genetically modified rat comprising a humanized TRKB locus

    Expires Mon Aug 18 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 11414494

    Anti-GITR antibodies and uses thereof

    Expires Mon Aug 11 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 11407822

    Treatment of fibrodysplasia ossificans progressiva

    Expires Mon Aug 04 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 11407813

    Anti-VEGF protein compositions and methods for producing the same

    Expires Mon Aug 04 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 11396544

    Bispecific anti-CD28 × anti-CD22 antibodies and uses thereof

    Expires Mon Jul 21 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 11384153

    Bispecific anti-BCMA x anti-CD3 antibodies and uses thereof

    Expires Mon Jul 07 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 11377502

    Anti-MSR1 antibodies and methods of use thereof

    Expires Mon Jun 30 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 11370843

    High affinity antibodies to human IL-6 receptor

    Expires Mon Jun 23 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 11369896

    Methods for quantitating individual antibodies from a mixture

    Expires Mon Jun 23 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 11365265

    Anti-C5 antibody combinations and uses thereof

    Expires Mon Jun 16 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 11359246

    Treatment of obesity with G-protein coupled receptor 75 (GPR75) inhibitors

    Expires Mon Jun 09 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 11352417

    Method of treating an allergy with allergen-specific monoclonal antibodies

    Expires Mon Jun 02 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 11351256

    Room temperature stable lyophilized protein

    Expires Mon Jun 02 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 11352446

    Methods of making multispecific antigen-binding molecules

    Expires Mon Jun 02 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 11345715

    Biologically active molecules, conjugates thereof, and therapeutic uses

    Expires Mon May 26 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 11331332

    Treatment of increased lipid levels with sterol regulatory element binding protein cleavage-activating protein (SCAP) inhibitors

    Expires Mon May 12 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 11319375

    Methods and compositions for treating subjects having rheumatoid arthritis

    Expires Mon Apr 28 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 11306155

    Methods for treating patients with heterozygous familial hypercholesterolemia (heFH) with an anti-PCSK9 antibody

    Expires Mon Apr 14 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 11306135

    Anti-VEGF protein compositions and methods for producing the same

    Expires Mon Apr 14 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 11306148

    Anti-NPR1 antibodies and uses thereof

    Expires Mon Apr 14 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 11299532

    Anti-VEGF protein compositions and methods for producing the same

    Expires Mon Apr 07 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 11291636

    Polymer protein microparticles

    Expires Mon Mar 31 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 11292842

    Anti-PD-1 antibodies for treatment of lung cancer

    Expires Mon Mar 31 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 11292847

    Methods for treating atopic dermatitis by administering an IL-4R inhibitor

    Expires Mon Mar 31 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 11286290

    Anti-VEGF protein compositions and methods for producing the same

    Expires Mon Mar 24 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many patents does Regeneron UK have?

837 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).

When do Regeneron UK patents expire?

26 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.

Where does this data come from?

USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.

Data attribution: Data sources · Patent directory

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.